The effect of ribavirin to treat previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity  by EVERARD, M.L. et al.
The effect of ribavirin to treat previously
healthy infants admitted with acute bronchiolitis
on acute and chronic respiratory morbidity
M. L. EVERARD*, A. SWARBRICK*, A. S. RIGBY{ AND A. D. MILNER*
*Paediatric Respiratory Unit, Queens Medical Centre, Nottingham, U.K. and {Division of Child Health, Sheffield
Children’s Hospital, Sheffield, U.K.
The role of ribavirin in the treatment of acute bronchiolitis is controversial. It has been suggested that the use of
ribavirin may be of benefit during the acute illness and may reduce subsequent recurrent respiratory morbidity. This
randomized, double-blind, placebo-controlled study was designed to determine whether ribavirin administered
during the acute illness would have an influence on respiratory morbidity during both the acute illness and during
the following year. Bronchial reactivity 6 months after the acute illness was also assessed. Forty previously well
infants with moderately severe acute bronchiolitis were recruited during three winter epidemics. Subjects received
study medication for 18 h a day. Management was otherwise unaltered. Subjects were evaluated daily by the
investigator and subsequently assessed at 6 weeks, 6 months and 1 year following the acute illness. Assessment of
bronchial hyper-responsiveness was assessed at 6 months of age using total body plethysmography and an
established ultra-sonically nebulized distilled water challenge.
A total of 40 patients (21 ribavirin, 19 placebo) were entered into the study. The two groups did not differ with
respect to age, gender or clinical severity on entry to the trial. No significant differences were identified in the rate of
clinical improvement over the first 24 h, the time to discharge, bronchial responsiveness at 6 months of age,
frequency of significant respiratory symptoms over the first year of life and the frequency of prescribed
bronchodilators and inhaled steroids during the year of follow-up.
This study was unable to demonstrate any clinical benefit from the use of ribavirin in the acute illness or during
subsequent follow-up for 1 year.
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Acute bronchiolitis is the commonest form of lower
respiratory tract infection in infancy, with 0?5–2% of all
infants being hospitalized with this condition during the
winter following their birth (1–3). In the majority of cases
the causative organism is the respiratory syncytial virus
(RSV). For the vast majority of infants admitted with this
condition, careful monitoring and good supportive care
remains the cornerstone of management (4,5). It has been
suggested that the anti-viral drug, ribavirin, has a role in the
treatment of these infants but despite the fact that ribavirin
has been licensed for the treatment of infants with
respiratory syncytial virus for more than a decade, its place
in the treatment of RSV bronchiolitis remains controver-Received 15 September 2000 and accepted in revised form 2
January 2001.
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0954-6111/01/040275+06 $35?00/0sial. This has been reflected in the position of the American
Academy of Pediatrics recent reassessment of the indica-
tions for its use which resulted in the recommendation that
practitioners should be ‘allowed to decide whether ribavirin
therapy is appropriate by taking into account the particular
clinical situation and their own preferences’ (6).
Previous randomized double-blind studies have concen-
trated on the effect of this drug on the course of the acute
respiratory illness. However, the morbidity associated with
RSV bronchiolitis is not confined to the acute illness in that
the majority of infants admitted to hospital with acute
bronchiolitis will subsequently experience recurrent lower
respiratory tract symptoms, particularly in the pre-school
years (7–9). The cause of these recurrent respiratory
symptoms is unclear (4,10). It may be that certain forms
of pre-existing respiratory dysfunction predispose indivi-
dual infants to both acute bronchiolitis and to the
subsequent recurrent symptoms. Alternatively, changes in
the lower airway structure or physiology caused by the
intense inflammation present in the airways of infants with
acute bronchiolitis (11) may contribute to the subsequent# 2001 HARCOURT PUBLISHERS LTD
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suggestion that an RSV-specific IgE response contributes to
subsequent morbidity (12), although recent studies suggest
that this is unlikely (13,14). Previous studies have provided
convincing evidence that RSV bronchiolitis does not
promote expression of atopy (4,7), although a recent study
suggests that this may be the case (15). If recurrent
symptoms are attributable to the effects of virally-induced
inflammation, then it is possible that the use of ribavirin
early in the illness would limit viral replication, limit the
intensity of the inflammatory process, and so reduce the
frequency of post-bronchiolitic symptoms.
This randomized, controlled, double-blind study was
designed to determine whether administering ribavirin to
previously healthy infants admitted with acute bronchiolitis
would reduce the frequency of lower respiratory tract
symptoms in the year following admission. In addition, we
studied the effect of ribavirin therapy on the course of the
acute illness and assessed bronchial responsiveness at 6
months following the acute illness using a nebulized
distilled water challenge.
Methods
Forty infants admitted to the paediatric wards of the
Queens Medical Centre, Nottingham with moderately
severe bronchiolitis were recruited during three RSV
epidemics. All were previously fit and had no high risk
factors for severe disease. All were entered into the study
within 12 h of admission. To enter the study the definition
of ‘bronchiolitis’ used in the U.K. and Australia was used
(16,17), that is, patients with evidence of upper respiratory
tract viral illness who develop lower respiratory tract
involvement characterized by airways obstruction and
widespread crepitations on auscultation. Wheeze and
rhonchi may or may not be present. Patients were entered
into the study before their RSV status was assessed by an
immunofluorescence technique to ensure that they were
entered into the study as soon after admission as possible in
line with the suggestion that the early use of ribavirin is
associated with the greatest benefit.
These patients were randomized to receive 6 g of ribavirin
in 180ml of water by the Small Particle Aerosol Generator
(SPAG). The medication was administered following a
standard regime over 18 h per day. Normal saline was used
for the placebo since previous studies had been criticised for
using distilled water as placebo. It has been suggested that
nebulized distilled water may adversely affect these infants
by inducing bronchoconstriction (18). However, the output
of the SPAG is so low that this seems unlikely (19).
The study was approved by the local Ethics Committee
and informed consent was obtained from the parents of all
subjects.
ACUTE ILLNESS
Subjects were evaluated daily until discharge and their
clinical status was assessed by one investigator (M.L.E.),
who undertook assessments in a blinded fashion. In orderto ensure that the assessment was blinded the SPAG was
switched off and any crystalline ribavirin removed from
tubing, bedding and patient before the patient was assessed.
Patients were assigned a daily severity score. No scoring
that accurately reflects the severity of the acute illness has
been validated. The arbitrary scoring system chosen used a
scale of 1–10; 1 representing no symptoms and 10 would be
applied to a ventilated infant. Time until discharge from
hospital was recorded with an additional outcome of ‘fit for
discharge’ being recorded. ‘Fit for discharge’ was defined as
time when patients were deemed to be medically fit for
discharge. Time to discharge can be influenced by social
factors and this second parameter was included to try and
ensure social factors did not obscure treatment effects.
Duration of supplementary oxygen were all recorded.
FOLLOW-UP
Following discharge, subjects were reviewed at 6 weeks, 6
months and 1 year after discharge. Patients were provided
with diaries at each visit in which they were asked to record
all respiratory symptoms, medical attention for any
respiratory symptoms and any medication prescribed for
respiratory symptoms. The dates of onset and resolution of
symptoms were also recorded. Parents were asked to record
any of the following respiratory symptoms—running nose,
cough, wheeze and shortness of breath.
Bronchial hyper-responsiveness was assessed using an
ultra-sonic distilled water challenge as previously estab-
lished in our laboratory (20). A number of approaches to
assessing bronchial hyper-responsiveness in infants using
total plethysmography have been described using pharma-
cological agents (21–23). However we chose to use a ‘non-
specific’ hypo-osmolar challenge as it was felt that this may
be more clinically relevant than using a mediator such as
histamine. This approach has been used by a number of
centres studying bronchial responsiveness in adults and
older children. The use of an ultra-sonic distilled water
challenge was evaluated in 100 infants prior to the
commencement of this study (20).
A positive response to the ultra-sonic challenge was
defined as a fall in specific airways conductance (sGaw) of
greater than 20% from baseline based on previous work
assessing reproducibility of measurements (20). Airways
conductance was assessed using absolute total body
plethesmography which had been used to assess airways
conductance for more than four decades (24) and was used
in our unit for more than a decade prior to this study. The
technique has been used extensively over recent years,
providing insights into a wide variety of cardiopulmonary
disease and response to therapy (24). The principles and
practical considerations have been recently been reviewed
in considerable detail (24). The total body plethysmograph
used in this study was a purpose built unit constructed
by the Department of Medical Physics, Queen’s Medical
Centre, Nottingham based on a standard design (20).
The volume of the plethysmograph was 65 l. Once sedated,
with 100mg kg71 of chloral hydrate, infants were placed
in the plethysmograph and allowed to settle. Baseline
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and there were minimal changes (less than 0?58) in the slope
of the box pressure/slope readings from the face of the
oscilloscope over a 5-min period. Infants then inhaled
ultrasonically nebulized distilled water for 2min adminis-
tered via an Intersurgical Variosonic nebulizer, with the
aerosol being delivered via the tube connecting the infants
face mask to the outside of the box ensuring that the box
and infant were not disturbed. Measurements of sGaw were
made at 2-min intervals for a total of 12min after the
nebulization was completed.
STATISTICS
The ribavirin and placebo groups were analysed by
comparison of the means: 95% confidence intervals were
calculated for the mean differences. The results presented in
Table 3 give both unadjusted and adjusted mean differences
(adjusting for age at admission, sex and weight of baby).
The adjusted analyses were carried out by linear least-
squares regression method on each of five outcome
measures (i.e. change in score, days in oxygen, changes in
oxygen saturation measured in air, days to discharge and
days fit for discharge). For each regression analysis, the
residuals followed an approximate normal distribution. A
nominal significance level of 5% was assumed throughout.
Results
Demographic details of the patients are included in Table 2.
The two groups did not differ in respect to age, weight orTABLE 2. Demographic data for patients recruited to study.
Data for mean and range shown
Ribavirin Placebo
Gender 9m 12f 9m 10f
Age (days) 93?7 89?4
(15–188) (16–266)
Weight (kg) 5?7 5?4
(3?1–9?3) (1?9–9?0)
TABLE 1. Lower respiratory tract symptoms and therapy
required during the first year following admission to





Admitted with LRT symptoms 2 3
Bronchodilators 5 8
Inhaled steroids 2 1
No LRT symptoms 4 5gender. Clinical severity at entry to the trial as assessed by
arterial oxygen saturation in air and clinical score was not
significantly different between the groups. Both groups had
a median arterial oxygen saturation in air of 89% and the
baseline clinical scores at entry were mean 5?9 (median 6?0)
in the placebo group compared to the ribavarin group
mean 6?0 (median 6?0). Of the 40 patients entered
into the study 38 were RSV-positive. Of the two RSV-
negative patients one received placebo and one ribavirin.
They both had relatively long admissions of 8 and 11 days
respectively.
During the acute illness there was no statistical difference
in the rate of improvement of clinical scores, duration of
oxygen therapy or time to discharge (Table 3). The duration
of hospitalization was very similar to that reported for
centres in the U.K., U.S.A. and Australia (25).
There were no significant differences in the frequency of
reported lower respiratory tract symptoms between the two
groups in the 35 patients followed to 1 year post-discharge
or in any of the variables noted in Table 1. Four patients
were lost to follow-up and one patient, who had received
ribavirin, died some months after discharge from an illness
consistent with an autoimmune enteropathy.
A total of 28 patients underwent assessment of bronchial
hyper-responsiveness, of whom five woke before comple-
tion of the study. A small number of patients were lost to
follow-up as noted above. Lung function measurements
were not obtained in others because their parents declined
to have their infants sedated. Increased bronchial respon-
siveness defined as a fall in sGaw of 420% was noted in
three of the 11 patients treated with ribavirin and in one of
12 patients treated with placebo.
Discussion
This study was unable to show any significant benefit when
ribavirin was used to treat previously healthy infants
admitted with moderately severe bronchiolitis. This applies
to both the acute illness and to subsequent respiratory
morbidity. Furthermore, we were unable to show any
difference in bronchial hyper-responsiveness 6 months after
the acute illness. This study does not support the routine
use of this drug in the treatment of acute bronchiolitis in
previously healthy individuals.
Other studies utilising ribavirin to treat previously
healthy infants have included relatively few patients and
have not provided any evidence that ribavirin has a
significant impact on the clinical course of infants admitted
with acute bronchiolitis. A recent systematic review (26)
and meta-analysis which included studies involving high
risk patients was unable to identify evidence that ribavirin
has any significant impact on the course of the disease.
They concluded that ribavirin does not significantly reduce
mortality or duration of hospitalization, prevent deteriora-
tion or reduce duration of oxygen dependency. Our results
support these conclusions, though interestingly those
patients treated with ribavirin tended to remain in hospital
longer than those treated with placebo. There was one
patient who remained in hospital significantly longer than
TABLE 3. Ribavirin vs. controls: comparison of mean values both unadjusted and adjusted for age at admission, weight and sex




Unadjusted 3?36 2?52 0?84 (70?63, 2?31) 0?41
Adjusted 2?72 1?92 0?80 (70?73, 2?32) 0?43
Change in score (day 1, day 0)
Unadjusted 70?83 71?05 0?22 (70?67, 1?11) 0?83
Adjusted 72?11 72?25 0?14 (70?72, 1?01) 0?89
Change in oxygen saturation measured in air (day 17day 0)
Unadjusted 2?05 0?57 1?48 (71?59, 4?55) 0?15
Adjusted 4?03 2?47 1?56 (71?56, 4?68) 0?13
Days to discharge
Unadjusted 5?58 3?95 1?63 (70?09, 3?35) 0?11
Adjusted 4?94 3?36 1?58 (70?19, 3?35) 0?12
Days fit for discharge
Unadjusted 4?77 3?86 0?91 (70?63, 2?44) 0?37
Adjusted 3?43 2?69 0?74 (70?82, 2?30) 0?46
Notes. All P-values not statistically significant at an arbitary 5% level.
Adjusted mean differences from multiple regression analyses.
For all five regression analyses, the residuals followed an approximate normal distribution.
Changes in score at day 1 not recorded for one infant (ribavirin). Days fit for discharge not recorded in two babies (both
ribavirin).
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convalescent period. However, this trend persists even
when this patient was removed from the analysis.
A recently published retrospective, non-randomized
study with a high drop-out rate (27) suggested that patients
treated with ribavirin reduced the frequency of lower
respiratory tract symptom in the following year. We found
no evidence for such an effect and indeed our findings are
consistent with two recently published studies which
followed up patients included in randomized placebo-
controlled trials 10 years after their admission to hospital
(28,29). These studies found no evidence that ribavirin had
a long-term beneficial effect on symptoms or lung function.
If ribavirin therapy were to have an effect on subsequent
symptoms it is necessary to propose that the illness itself is
capable of inducing changes that predispose patients to
subsequent symptoms and ribavirin prevents this. The lack
of proven ecacy in the acute illness would suggest that the
effects of ribavirin on the inflammatory process, if any,
were relatively small and therefore unlikely to have a
significant effect on the long-term sequelae. It is of course
possible that ribavirin might have actions other than simply
limiting viral replication that influence long term outcome
but there is currently no evidence for this.
Our findings that 75% of the ribavirin treated group and
73?7% of the placebo group experience further lower
respiratory tract symptoms in the year following admission
is in line with previously published studies (30,31). Overall,
only 17% of the 23 infants undergoing distilled water
challenge demonstrated evidence of bronchial hyper-
responsiveness, a much lower percentage than observed inother groups of recurrently wheezy infants (20). The low
incidence of bronchial hyper-reactivity observed in these
infants may indicate that bronchial hyper-responsiveness is
not a major contributory factor in the subsequent episodes
of lower respiratory tract symptoms. As noted in the
introduction, the relationship between the acute illness and
subsequent recurrent respiratory morbidity remains un-
clear.
The long running debate surrounding the use of ribavirin
in acute bronchiolitis is in large part due to the fact that it
was introduced with limited data to support its use. Early
studies with ribavirin contained relatively few patients in
stark contrast to the recent large randomized double-blind,
placebo-controlled studies involving more than 1000
patients assessing the ability of synthetic monoclonal
antibodies to prevent significant disease in high risk
infants (32). It is possible that significant differences
may have been observed in our study if larger numbers
had been included. If this study were to be repeated a
sample size of 104 patients would be required to show a
significant difference in days to discharge using a power of
80% and a significance level of 5% though it should
be remembered that this is based on a trend to earlier
discharge in the placebo group. The very small differences
in the other outcomes would indicate that much
larger numbers than 104 would be required to demonstrate
a significant difference. It seems unlikely that such
small differences could translate into clinically significant
effects.
In summary, this prospective, randomized, placebo-
controlled trial failed to identify any short- or long-term
RIBAVIRIN: ACUTE AND CHRONIC RESPIRATORY MORBIDITY 279benefits that could be attributed to the use of ribavirin to
treat previously healthy infants.
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